ArticleDie Ophthalmologie2022
[Phototherapeutic keratectomy for epithelial basement membrane dystrophy : Impact of excimer laser systems used on the changes of visual acuity, refraction and astigmatism].
Article in Die Ophthalmologie, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed, 5 citations in OpenAlex.
- Higher-Order Aberrations, Corneal Density, and Visual Acuity After Excimer Laser Phototherapeutic Keratectomy (PTK) for Epithelial Basement Membrane Dystrophy.Journal of ophthalmology · 2025Article
- Corneal Epithelial Wavefront Error as a Novel Diagnostic Marker for Epithelial Basement Membrane Dystrophy.Life (Basel, Switzerland) · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundExcimer laser-assisted phototherapeutic keratectomy (PTK) has become established as the gold standard in treatment of epithelial basement membrane dystrophy (EBMD), commonly also known as map-dot-fingerprint dystrophy (MDF). At the Department of Ophthalmology, Saarland University Medical Center in Homburg/Saar, systems from Zeiss Meditec and Schwind have been used. The outcomes of both were compared in this study. PATIENTS AND
methodsThe retrospective study included patients who underwent PTK with a diagnosis of MDF between 2007 and 2017. A total of 170 operations were performed using Zeiss Meditec MEL-70 (Carl Zeiss Meditec AG, Jena, Germany) and 98 using a Schwind eye-tech-solutions Amaris 750S laser (Schwind eye-tech-solutions GmbH, Kleinostheim, Germany). Preoperative and postoperative data for visual acuity, refraction and astigmatism as well as curvature data from the Pentacam and endothelial cell count were collected. The follow-up period averaged 8 months.
resultsIn both groups visual acuity postoperatively was significantly better (Zeiss: p < 0.001, Schwind p < 0.004). The improvement in the Schwind group was less than in the Zeiss group, which is the reason why there was a significant difference between the laser systems postoperatively (p < 0.017). There were no significant changes regarding the spherical equivalent after PTK. Regarding astigmatism, there was a significant decrease in the Zeiss group (p < 0.042), while it did not change significantly in patients treated with Schwind laser (p < 0.217). Overall, this led to a significant postoperative difference between both laser systems (p < 0.014).
conclusionThe PTK can be recommended as an effective treatment method for patients with EBMD, regardless of the laser systems used. Patients benefit from long relief from recurrences with improved or constant visual acuity and stable refraction.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.